The Goldman Sachs Group Increases Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $8.00

Amneal Pharmaceuticals (NASDAQ:AMRX) had its price target raised by investment analysts at The Goldman Sachs Group from $6.25 to $8.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target points to a potential upside of 22.89% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Truist Financial reaffirmed a “buy” rating and set a $9.00 price target (up previously from $7.00) on shares of Amneal Pharmaceuticals in a research report on Monday. Barclays increased their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, January 29th. Piper Sandler boosted their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Finally, StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 4th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.25.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $6.51 on Monday. The firm has a market cap of $2.00 billion, a PE ratio of -11.62 and a beta of 1.33. Amneal Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $6.90. The company’s fifty day simple moving average is $5.79 and its 200-day simple moving average is $5.34. The company has a quick ratio of 0.97, a current ratio of 1.65 and a debt-to-equity ratio of 121.31.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Friday, March 1st. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.05 by $0.07. The firm had revenue of $616.98 million for the quarter, compared to analysts’ expectations of $630.67 million. Amneal Pharmaceuticals had a negative net margin of 6.76% and a positive return on equity of 234.06%. Equities research analysts expect that Amneal Pharmaceuticals will post 0.5 EPS for the current fiscal year.

Institutional Trading of Amneal Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Gladius Capital Management LP bought a new position in Amneal Pharmaceuticals in the 3rd quarter valued at about $39,000. Sherbrooke Park Advisers LLC bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth approximately $54,000. Trexquant Investment LP bought a new stake in Amneal Pharmaceuticals in the 4th quarter valued at $65,000. TCG Advisory Services LLC acquired a new position in Amneal Pharmaceuticals in the 4th quarter valued at $91,000. Finally, Aigen Investment Management LP acquired a new position in shares of Amneal Pharmaceuticals in the third quarter valued at about $118,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.